Targeting Senescence to Reduce Osteoarthritis Pain and cartilagE Breakdown (ROPE) — ROPE  

Osteoarthritis, Knee Clinical Trial

Official title: Targeting Senescence to Reduce Osteoarthritis Pain and cartilagE Breakdown (ROPE)

Status Withdrawn

Clinical Trial Summary

Symptomatic knee osteoarthritis (OA) is the most common joint disorder in the U.S. and a leading cause of disability. Increasing age, obesity, and previous injury increase the lifetime risk of knee OA, but these factors are also independently associated with increased cellular senescence. Senescent cells accumulate in many tissues and contribute to chronic pathologies, linked to the secretion of pro-inflammatory factors collectively known as the senescence-associated secretory phenotype. In OA, senescent cells promote production of cytokines, chemokines, and matrix-degrading enzymes involved in progressive cartilage breakdown. The senolytic supplement fisetin alters the inflammatory and catabolic cartilage responses, which may clinically lessen OA pain while also slowing progressive cartilage breakdown. The purpose of this double-blind, randomized clinical trial is to compare 2 fisetin dosing regimens versus placebo. Sixty patients with mild to moderate knee OA will be assessed at baseline and 3 months in an effort to: determine if 2 different fisetin dosing regimens lessen pain and functional impairment compared to placebo, compare progressive changes in senescent cell activity and biomarkers of cartilage degradation between different fisetin dosing regimens and placebo, and assess acceptability and feasibility of 2 fisetin dosing regimens.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Osteoarthritis
• Osteoarthritis, Knee

• NCT number: NCT04770064
• Study type: Interventional
• Source: University of Kentucky
• Status: Withdrawn
• Phase: Phase 1/Phase 2
• Start date: June 2023
• Completion date: May 31, 2024